As bstract. We have already demonstrated that a hyperinsulinemic, diabetic subject secreted an abnormal insulin in which serine replaced phenylalanine B24 (Shoelson S., M. Fickova, M. Haneda, A. Nahum, G. Musso, E. T. Kaiser, A. H. . Proc. NatL. Acad. . High performance liquid chromatography analysis now shows that the circulating insulin in several other family members also consists of a mixture of the abnormal human insulin B24 (Phe -+ Ser) and normal human insulin in a ratio of -9.5:1 during fasting. Although all affected subjects show fasting hyperinsulinemia, only the propositus and her father are overtly diabetic. Analysis of the serum insulin from two nondiabetic siblings revealed that normal insulin increased from -2 to 15% of total serum insulin after the ingestion of glucose and that the proportion ofthe normal hormone plateaued or fell while the level oftotal insulin continued to rise. Animal studies involving the graded intraportal infusion of equimolar amounts of semisynthetic human [SerB24]-insulin and normal human insulin in pancreatectomized dogs (to simulate the secretion of insulin due to oral glucose in man) also showed both a rise in the fraction of normal insulin that reached the periphery and the attainment of a brief steady state in this fraction while total insulin levels continued to rise. Separate experiments documented a decreased hepatic extraction, a decreased metabolic clearance rate, and an increased plasma half-life of human
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As bstract. We have already demonstrated that a hyperinsulinemic, diabetic subject secreted an abnormal insulin in which serine replaced phenylalanine B24 (Shoelson S., M. Fickova, M. Haneda, A. Nahum, G. Musso, E. T. Kaiser, A. H. Rubenstein, and H. . Proc. NatL. Acad. Sci. USA. 80:7390-7394). High performance liquid chromatography analysis now shows that the circulating insulin in several other family members also consists of a mixture of the abnormal human insulin B24 (Phe -+ Ser) and normal human insulin in a ratio of -9.5:1 during fasting. Although all affected subjects show fasting hyperinsulinemia, only the propositus and her father are overtly diabetic. Analysis of the serum insulin from two nondiabetic siblings revealed that normal insulin increased from -2 to 15% of total serum insulin after the ingestion of glucose and that the proportion ofthe normal hormone plateaued or fell while the level oftotal insulin continued to rise. Animal studies involving the graded intraportal infusion of equimolar amounts of semisynthetic human [SerB24]-insulin and normal human insulin in pancreatectomized dogs (to simulate the secretion of insulin due to oral glucose in man) also showed both a rise in the fraction of normal insulin that reached the periphery and the attainment of a brief steady state in this fraction while total insulin levels continued to rise. Separate experiments documented a decreased hepatic extraction, a decreased metabolic clearance rate, and an increased plasma half-life of human
[SerB24]-insulin within the same parameters as those determined for normal human insulin. These results form Please address correspondence to Howard S. Tager, Department of Biochemistry, University of Chicago.
Introduction
Three individuals from separate families are now known to secrete distinct, abnormal insulins that result from insulin-gene mutations in man (1) . By the techniques of protein chemistry and recombinant DNA technology, the abnormal insulins from two of these individuals have been identified as human insulin B25 (Phe -Leu) (human [LeuB25]-insulin, insulin Chicago) (1) (2) (3) (4) (5) and human insulin B24 (Phe -Ser) (human [SerB24]_ insulin, insulin Los Angeles) (1, 6, 7) ; the structure of the abnormal insulin from the third remains to be determined. Because small amounts of normal insulin (in addition to large amounts of abnormal insulin) were detected in the serum of all three individuals (1) , and because restriction endonuclease mapping has shown that two have both normal and abnormal insulin gene alleles (1, (4) (5) (6) , it seems that normal and abnormal insulin gene alleles are coexpressed in affected subjects. Clinical characteristics ofthese patients with mutant insulins have been summarized (8) and include hyperinsulinemia; a lack of evidence for insulin resistance due to contrainsulin hormones, insulin antibodies, insulin receptor antibodies, or decreased numbers of insulin receptors; a normal response to exogenous insulin; a reduced biological activity ofendogenous insulin; and a reduced C-peptide/insulin molar ratio. Glucose intolerance and overt diabetes may or may not be present.
Although the amino acid substitutions that occur in abnormal human insulins are themselves genetically and chemically important (1, 5-7, 9, 10) , the greatest impact of these mutant hormones in studies of normal and abnormal human physiology derives from their altered potential for recognition by cellular insulin receptors and from their reduced ability to stimulate appropriate cellular responses: Human [LeuB2S]-insulin and human [Ser524]-insulin have only -2 and 16%, respectively, of the biological potency of normal human insulin (7, (10) (11) (12) . Determining the consequences of the secretion of low-activity insulins in man thus requires separate consideration of insulin secretion rates in response to appropriate stimuli, receptor binding and biological activities ofthe secreted insulin, and metabolic clearance rates of each circulating hormone form.
The current investigation was prompted by the opportunity to study seven members of a family, the propositus of which had been shown to secrete human [Ser524]-insulin (7) , and to examine the disposition of semisynthetic human [Ser5241-insulin by using an animal model. Our results show that (a) six of seven family members tested express the abnormal gene for human
[Ser524]-insulin, but only two are diabetic; (b) diabetes within this group appears to be associated with both altered rates of insulin secretion and expression of the gene coding for [Ser524]-insulin; and (c) the hyperinsulinemia and the low C-peptide/ insulin molar ratio that are characteristic ofthese patients probably arise from a slow clearance of the abnormal insulin from the circulation.
Methods
Subjects and clinical evaluation. All subjects in this report were between 90% and 110% ofideal body weight and were members ofa single family spanning three generations. Approval for these studies was obtained from the Clinical Investigation Committees ofthe University ofChicago and the University of Southern California. The propositus, a 29-yr-old white female, was identified as being glucose intolerant -3 yr ago by Dr. Wishner (Los Angeles, CA). The propositus' 59-yr-old father is an insulin-treated diabetic; her mother (59 yr old), two brothers (26 and 32 yr old), a sister (23 yr old), and a niece (3 yr old) are all asymptomatic. Fasting blood was obtained from each of these subjects for determination of serum immunoreactive insulin and glucose; additional samples of serum were taken for high performance liquid chromatography (HPLC)' analysis of serum insulin (see below). Oral glucose tolerance tests (100 g of glucose ingested after an overnight fast) were performed on the propositus, a brother, and a sister. Venous blood was drawn for the determination of serum insulin, plasma glucose, and plasma C-peptide before glucose ingestion and at 30, 60, 90, and 120 min after glucose ingestion. Enough blood was obtained from the brother and sister for purification and HPLC analysis of serum insulin at the time of each oral glucose tolerance test.
Serum insulin purification and HPLC analysis. Insulin from 2-10 ml of human or dog serum was purified by immunoaffinity chromatography with guinea pig antiporcine insulin antiserum covalently coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals Inc., Piscataway, NJ) (1, 13 given 25 g of glucose orally and the infusion rate was progressively increased at 5-min intervals, so that by 60 min the rate was 21 pmol/ kg per min. The infusion rate was then progressively reduced over an additional 120-min (see Fig. 5 ) and the basal rate of infusion was resumed for 60 min. Infusion rates were chosen to simulate the rise and fall in peripheral insulin levels that occur in response to the administration of oral glucose in man. Blood samples for the determination of immunoreactive insulin and glucose, and for HPLC analysis of serum insulin, were drawn from a catheter placed in the femoral artery. Arterial blood glucose levels were 98, 286, 126, 89, and, 81 mg/dl at 0, 60, 120, 180, and 240 min, respectively, during the period of the graded infusion.
The The infusion was stopped after a total of 50 min had elapsed; samples of blood were drawn at 1-to 5-min intervals from the femoral artery for an additional 20-30 min to evaluate the half-life of the infused insulin. After levels of infused insulin had been allowed to decay, the same animal was infused with the second of the two insulins using the identical protocol. Hepatic plasma flow, hepatic insulin extraction, and metabolic clearance rate were calculated as previously described (16, 17) . Data are expressed as mean±SEM. The order in which the insulins were infused did not affect any of these parameters.
Results HPLC analysis and immunometric detection ofserum insulin. Figure 1 . HPLC analysis of serum insulin from the propositus and six members of her family. Serum insulin was purified by immunoaffinity chromatography and was subjected to HPLC and further analysis as described in Methods. Amount of immunoreactive insulin is plotted against HPLC fraction number in each of the profiles. Arabic numerals identify the individual with respect to subsequent experiments; subject 3 is the propositus. Roman numerals I-IV identify the elution positions of human [Ser524]-insulin, bovine insulin, normal human insulin, and porcine insulin, respectively. Columns to the right of the figure list the fasting serum levels of immunoreactive insulin and glucose determined for each of the seven subjects.
(subject 1), however, secretes only the normal hormone. In each of subjects 2 through 7, the ratio of the serum concentration of abnormal insulin to that of normal insulin is >9:1. Note that the immunoaffinity chromatography-purified serum insulin from the father ofthe propositus (subject 2), an insulin-treated diabetic patient, consists of large amounts of human [SerB12]-insulin, small amounts of normal human insulin, and small amounts of beef insulin and pork insulin, the last two of which result from exogenous insulin therapy. As noted before (8) , all subjects who secrete the abnormal human insulin show marked fasting hyperinsulinemia, whereas only two of the subjects, the propositus and her father (subjects 3 and 2), show fasting hyperglycemia.
Taken together, the results of Fig. 1 (18) and that immunometric equivalency must be separately assessed for each new or uncommon insulin analogue under investigation.
Responses to oral glucose. To examine in detail the glucose responses of both diabetic and nondiabetic members of the family that secretes human [SerB24]-insulin, subjects 3, 4, and 5 ( Fig. 1) were given oral glucose tolerance tests. Results of these tests, which documented circulating levels of insulin, Cpeptide, and glucose, are presented in Fig. 3 . It is important that all three subjects showed fasting hyperinsulinemia. The propositus (subject 3) also showed fasting hyperglycemia and the marked elevations in plasma glucose levels typical of a diabetic patient after glucose ingestion. In contrast, her two siblings (subjects 4 and 5) exhibited a glucose tolerance that approached that expected for normal individuals: Despite an apparently delayed response (to 90 min) in attaining peak insulin levels, and despite the higher-than-normal serum concentrations of insulin (2 pmol/ml; normal = 0.3-0.8 pmol/ml) and C-peptide (4 pmol/ml; normal = 0.7-2.0 pmol/ml) eventually reached (19-21), most of the glucose levels in subjects 4 and 5 were within the normal range throughout the 2-h period. In this single comparison, increments in insulin and C-peptide, summed from measurements 30, 60, and 120 min after glucose ingestion were, respectively, 1.3 and 3.8 pmol/ml for subject 3; 2.8 and 7.8 pmol/ml for subject 4; and 2.8 and 6.9 pmol/ml for subject 5. Thus, it appears that the B cell secretion response of the diabetic propositus was only about half that of her two nondiabetic siblings over the period of the test. All three subjects showed C-peptide/total insulin molar ratios of - 1.5 Fig.  1 . The results of this analysis are presented in Fig. 4 , using the common format for presenting glucose tolerance data. As shown in a and b, the abnormal form ofthe hormone, human [SerB24]_ insulin, accounts for the major fraction of serum insulin at each time point. Further, for each of these two subjects, the fraction of serum insulin attributable to normal human insulin rose from the basal state upon ingestion oforal glucose and fell again while the level of total insulin continued to increase. In fact, the levels of normal insulin during fasting (0.04 pmol/ml, -6 microunits/ml), the rise in levels of normal insulin during early periods (to peak values of 0.23 pmol/ml, -33 microunits/ml), and the fall in levels of normal insulin to near basal values during later periods are indicative ofa relatively normal response to oral glucose; the character of the curves that reflect human [SerB24]-insulin secretion in response to oral glucose, and the high circulating levels of [SerB24]-insulin eventually reached are, however, clearly abnormal. Although the C-peptide/abnormal insulin molar ratio rose in parallel with the C-peptide/total insulin molar ratio during glucose stimulation of B cell secretion, the C-peptide/normal insulin molar ratio fell to 15-30% of its basal value under the same circumstances.
Animal models. The data in Fig. 4 show that the hyperinsulinemia present in subjects 4 A steady state infusion of the equimolar mixture of normal and abnormal insulins at a combined rate of 3.3 pmol/kg per min over a 60-min period resulted in a basal total serum insulin level of 0.37 pmol/ml (53 microunits/ml). Increasing and then decreasing the rate of infusion over a 4-h period (to mimic pancreatic insulin secretion associated with the administration of oral glucose; Fig. 5 a) resulted in total serum insulin levels that increased approximately fourfold by 60 min and then returned to near basal values by the end of the experiment (Fig.  5 b) . Although the normal and abnormal insulins were infused at equimolar concentrations, HPLC analysis of serum insulin at each of the time points shown in Fig. 5 demonstrated that the abnormal insulin always predominated in the peripheral circulation (Fig. 5 b) . Less than 5% of total serum insulin in the basal state was attributable to the normal hormone; even at its peak level, normal insulin accounted for <20% of total circulating insulin. Fig. 5 c shows that the fraction of total insulin attributable to the normal hormone rose rapidly early in the experiment, reached a transient steady state, and then fell while total insulin levels were still elevated. The high levels of total insulin achieved, the low fraction of total insulin attributable to normal insulin, and the rapid rates of change of normal insulin levels in this experiment all mimic results obtained in man (see Fig. 4 ).
Because the rates of infusion of human [SerB24]-insulin and normal human insulin were equal in the experiment shown in Fig. 5 , the elevated levels of total serum insulin and the low fraction of total insulin attributable to normal insulin most likely arose from different rates of clearance of the two insulin forms. Fig. 6 A number of studies have demonstrated (a) the need for interaction of insulin with its cellular plasma membrane receptor for subsequent hormone metabolism by the liver (23, 24) , (b) the saturation of hepatic insulin metabolism by increasing concentrations of the hormone (25) , (c) the regulation of hepatic insulin extraction by physiological stimuli (16) , and (d) the structural specificity of receptor-linked mechanisms for hepatic insulin metabolism (10) . Interaction of insulin with its receptor therefore seems to be a prerequisite for its metabolism and degradation, as well as for its action. Since human [SerB24]-insulin has only 16% of the biological activity of normal insulin (7), it is not surprising that its rate of metabolic clearance through the liver would be equivalently depressed. On the other hand, the C-peptide (which for subjects of this study is secreted in molar amounts equal to the sum of human [SerB24]-insulin and normal human insulin) is not subject to hepatic metabolism (26) . Given relatively normal fasting C-peptide levels in patients who secrete abnormal insulins, the low fasting C-peptide/insulin molar ratio typical of such individuals undoubtedly arises mostly from the slow metabolic clearance and high serum levels of the abnormal hormone. Similarly, the delay with which peripheral levels of [SerB24]-insulin reach a maximal value during B cell stimulation (relative to the period required for normal insulin; Fig. 4 
